Trial reportDrug design, development and therapy2025
Effects of Esketamine-Dexmedetomidine Combination on Immediate Postprocedural Oxygenation Index in Severe Pneumonia Patients Undergoing Bedside Fiberoptic Bronchoscopic Sputum Aspiration: A Prospective Randomised Controlled Trial.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The aim was to investigate the effect of esketamine-dexmedetomidine (ESK-DEX) combination on immediate postprocedural oxygenation index (OI) in severe pneumonia patients undergoing bedside fiberoptic bronchoscopic (FOB) sputum aspiration, and provide clinical reference. Methods: A total of 90 patients diagnosed with severe pneumonia receiving non-invasive mechanical ventilation (NIV) who underwent bedside FOB were randomly and evenly divided into three groups: Group C (local anesthesia alone), Group D (DEX alone), Group ED (ESK-DEX). The primary outcome was the OI immediately after procedure (T1). The secondary outcomes: the OI was calculated at 6 h (T2), 12 h (T3), and 24 h (T4) after procedure; the mean arterial pressure (MAP) and heart rate (HR) were assessed at the following time points: FOB tip passage through nostril (t1), glottis (t2), 5 minutes after procedure (t3), and upon procedure completion (t4); Additionally, perioperative adverse events were also documented. Results: The Group ED demonstrated significantly higher OI compared to Group C at T1 (mean difference, -8.1; 95% CI, -13.48, -2.64; Conclusion: Compared with conventional sedation protocols, the ESK-DEX combined regimen demonstrated superior OI preservation immediately after procedure, enhanced OI within 24 hours postoperatively, improved hemodynamic stability, and enhanced safety profile in severe pneumonia patients undergoing bedside FOB-guided suction therapy. This pharmacodynamic synergy addresses critical gaps in FOB sedation-simultaneously preventing hypoxemia, maintaining respiratory drive, and minimizing adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.